Syndax Pharmaceuticals (SNDX) PT Lowered to $29 at B.Riley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
BTIG Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
March 4, 2025 5:46 AM ESTBTIG analyst Justin Zelin reiterated a Buy rating and $43.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).
The analyst comments "SNDX reported 4Q24 earnings, detailing a solid $7.7M in net revenue for REVUFORJ (cons $2M) in the first 5 weeks of launch. Mgmt noted traction... More
Syndax Pharmaceuticals (SNDX) PT Lowered to $31 at Goldman Sachs
March 4, 2025 4:55 AM ESTGoldman Sachs analyst Chris Shibutani lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $31.00 (from $33.00) while maintaining a Buy rating.
The analyst comments "Syndax Pharmaceuticals (SNDX) reported 4Q24 results which featured the company's first reporting of commercial sales for Revuforj since the November 2024 approval. Revenues of $7.7mn (inclusive... More
